Clinical trial
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by…
NCT00464646 · NSABP Foundation Inc, Other · Completed
Key facts
| NCT number | NCT00464646 |
|---|---|
| Title | Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer |
| Official title | A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | Genentech, Inc. Industry International Drug Development Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab |
| Enrollment | 105 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2009 |
| Completion | May 1, 2014 |
| First posted | Apr 23, 2007 |
| Last update posted | Oct 25, 2021 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: